Ensysce Biosciences Inc (ENSC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ensysce Biosciences Inc (ENSC) has a cash flow conversion efficiency ratio of 5.233x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.50 Million) by net assets ($-669.01K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ENSC equity financing ratio to measure how much of total assets are equity-financed.
Ensysce Biosciences Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Ensysce Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Ensysce Biosciences Inc (ENSC) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Ensysce Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ensysce Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Svenska Aerogel Holding AB (publ)
ST:AERO
|
-0.179x |
|
Canasil Resources Inc.
V:CLZ
|
0.175x |
|
Classic Minerals Ltd
AU:CLZ
|
0.016x |
|
NFT Limited
NYSE MKT:MI
|
-0.596x |
|
Groupe Airwell Société anonyme
PA:ALAIR
|
-0.126x |
|
Cooper Metals Ltd
AU:CPM
|
-0.020x |
|
Aeon Metals Ltd
AU:AML
|
-0.016x |
|
Rokeby Resources Limited
AU:RKB
|
-0.061x |
Annual Cash Flow Conversion Efficiency for Ensysce Biosciences Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Ensysce Biosciences Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Ensysce Biosciences Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.88 Million | $-7.81 Trillion | -2706054.944x | -21.91% |
| 2024-12-31 | $3.38 Million | $-7.50 Trillion | -2219773.789x | -13410747.77% |
| 2023-12-31 | $-651.27K | $-10.78 Million | 16.552x | +272.89% |
| 2022-12-31 | $-4.03 Million | $-17.89 Million | 4.439x | +339.37% |
| 2021-12-31 | $-8.16 Million | $-8.24 Million | 1.010x | +439.31% |
| 2020-12-31 | $-6.66 Million | $-1.25 Million | 0.187x | +217.21% |
| 2019-12-31 | $186.17 Million | $10.99 Million | 0.059x | +1041.43% |
| 2018-12-31 | $197.39 Million | $-1.24 Million | -0.006x | -386.42% |
| 2017-12-31 | $195.27 Million | $-251.83K | -0.001x | -- |
About Ensysce Biosciences Inc
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR)… Read more